Jazz Pharmaceuticals plc Q2 2026 Earnings Recap

Jazz Pharmaceuticals shares rose 3.5% following a quarter driven by broad-based portfolio growth with multiple product lines exceeding expectations, particularly Xywav and Epidiolex. The market rewarded strong commercial execution and confidence in upcoming oncology launches.

Key Takeaways

• Total revenue reached $1.2 billion, up 16% year-over-year, reflecting sustained demand and effective commercialization across key products.
• Xywav net product sales grew 13% to $471 million, supported by continued new patient additions (+525 in the quarter) and an expanding active patient base now exceeding 17,000.
• Epidiolex sales increased 16% to $292 million, benefiting from ongoing educational efforts and the introduction of a novel capsule formulation targeting improved adherence in adult patients.
• Oncology portfolio showing early momentum as Ziihera generated $15 million in second-line BTC sales, capturing over 50% U.S. market share in the segment.
• Management highlighted readiness to launch zanidatamab in first-line HER2-positive metastatic GEA, leveraging existing commercial infrastructure to drive near-term growth.